Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus platinum-gemcitabine adjuvant therapy in high-risk non-metastatic upper tract urothelial carcinoma
ChiCTR2100053292Phase 2Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Nov 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, cisplatin and gemcitabine in upper tract urothelial carcinoma (UTUC), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Disease-free survival. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
tislelizumabcisplatingemcitabine
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on ChiCTR2100053292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053292.